scPharmaceuticals
Wednesday, June 05, 2024
Cardiovascular
Company Presentation Theater 3
Founded in 2013, scPharmaceuticals Inc. is commercializing products that advance patient care and reduce healthcare costs by enabling subcutaneous administration at home for products that were previously limited to intravenous (IV) delivery in the hospital setting. FUROSCIX, a pH neutral, subcutaneous formulation of furosemide was FDA approved in October 2022 and launched in February 2023 for the treatment of congestion due to fluid overload in patients with heart failure (HF). A sNDA is pending to expand he indication to chronic kidney disease (CKD) with a PDUFA date of Q1-2025.
Company Website:
https://www.scpharmaceuticals.com/
Lead Product in Development:
FUROSCIX (furosemide injection) 80 mg/10mL for subcutaneous administration
www.FUROSCIX.com
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Exchange
NASDAQ
Ticker
SCPH
Company HQ City
Burlington
Company HQ State
Massachusetts
Company HQ Country
United States
CEO/Top Company Official
John Tucker
Development Phase of Primary Product
Phase IV
Primary Speaker
)
)
)
)
)
)
){kind=logo}
){kind=logo}
.png/fit-in/500x500/filters:no_upscale())